Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 485 DKK 1.57%
Market Cap: 98.3B DKK
Have any thoughts about
Genmab A/S?
Write Note

Genmab A/S
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genmab A/S
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Long-Term Debt
kr925m
CAGR 3-Years
34%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Zealand Pharma A/S
CSE:ZEAL
Long-Term Debt
kr373.6m
CAGR 3-Years
43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Long-Term Debt
€338.9m
CAGR 3-Years
52%
CAGR 5-Years
61%
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Long-Term Debt
kr82.7m
CAGR 3-Years
-67%
CAGR 5-Years
-29%
CAGR 10-Years
2%
Bioporto A/S
CSE:BIOPOR
Long-Term Debt
kr3.5m
CAGR 3-Years
-23%
CAGR 5-Years
24%
CAGR 10-Years
43%
Saniona AB
STO:SANION
Long-Term Debt
kr40.3m
CAGR 3-Years
47%
CAGR 5-Years
69%
CAGR 10-Years
N/A
No Stocks Found

Genmab A/S
Glance View

Market Cap
94.2B DKK
Industry
Biotechnology
Economic Moat
Narrow

In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.

GMAB Intrinsic Value
2 682.76 DKK
Undervaluation 45%
Intrinsic Value
Price

See Also

What is Genmab A/S's Long-Term Debt?
Long-Term Debt
925m DKK

Based on the financial report for Jun 30, 2024, Genmab A/S's Long-Term Debt amounts to 925m DKK.

What is Genmab A/S's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
42%

Over the last year, the Long-Term Debt growth was 28%. The average annual Long-Term Debt growth rates for Genmab A/S have been 34% over the past three years , 42% over the past five years .

Back to Top